Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02003547
Other study ID # AMA0076-M-101
Secondary ID 2013-002334-21
Status Completed
Phase Phase 1
First received December 2, 2013
Last updated May 1, 2014
Start date September 2013
Est. completion date December 2013

Study information

Verified date May 2014
Source Amakem, NV
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Agency
Study type Interventional

Clinical Trial Summary

A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects


Description:

Each subject will receive the following treatments:

- Period 1: Formulation A (n = 14) or placebo (n = 7) twice daily for 7 days

- Period 2: Formulation B (n = 14) or placebo (n = 7) twice daily for 7 days

- Period 3: Formulation C (n = 14) or placebo (n = 7) twice daily for 7 days

There will be a minimum washout of 7 days between each treatment period (last dose of previous period to first dose of subsequent period


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy males and non-pregnant, non-lactating females, aged 35 to 65 years.

- Body mass index of =35kg/m2.

- IOP between 15 and 24 mmHg (inclusive) in both eyes at Screening Visits 1 and 2.

Exclusion Criteria:

- Women of child-bearing potential who have a positive pregnancy test.

- Any subject deemed by the investigator to have uncontrolled systemic hypertension

- Use of systemic, inhaled or ocular corticosteroid treatment within 90 days of screening or likely to require their use during the study period.

- Any screening laboratory abnormality that, in either the investigator's or the medical monitor's judgment, is considered to be clinically significant or a safety risk.

- History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study, or interfere with interpretation of the subject's study results.

- Participation in any other clinical study within 1 month of screening or during the study.

- Receipt of another investigational drug within 90 days of dosing in this study

- Diagnosis of any form of glaucoma.

- IOP >24 mmHg in either eye at any screening visit.

- Use of any ocular drops (including lubricating drops/artificial tears) during screening period or need for ocular drops during duration of study participation.

- In the opinion of the investigator, clinically significant eye trauma within 6 months of screening.

- Any intraocular ophthalmic procedure within 6 months of screening.

- Any ocular inflammation within 90 days of screening or a history of recurrent uveitis in either eye.

- Subjects with any known ocular disease and who are under care of a hospital ophthalmologist.

- Any condition preventing valid applanation tonometry measurement.

- Unable to discontinue contact lens wear during the study

- Visual acuity (VA) worse than 20/80 in either eye

- Subjects who are study site employees, or immediate family members of a study site or sponsor employee.

- History of any drug or alcohol abuse in the past 2 years.

- Regular alcohol consumption.

- Positive drugs of abuse test result.

- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
AMA0076

Placebo


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amakem, NV

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular Pressure The primary endpoint is the comparison of Intraocular Pressure assessments taken at pre-treatment on Day -1 and on Day 7 for each diurnal time point (0, 2, 4 and 8 h post-anticipated dose [Day -1] or post-dose [Day 7]) for each treatment period between active treatment and placebo. 7 days No
Secondary Safety and Tolerability The secondary endpoints are:
Comparison of hyperaemia assessments in each eye using a photographic rating scale on Day -1 (0 and 8 h post-anticipated dose) and Day 7 (0, 2, 4 and 8 h post dose)
Assessment of ocular surface photographic images of each eye on Day -1 and Day 7 (0 h).
Safety laboratory assessments, vital signs, 12-lead electrocardiogram (ECG), recording of Adverse Events and ophthalmic examination findings including visual acuity.
7 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A